|Articles|May 30, 2023

UTI Antibiotic Treatment: ‘Shorter is Better’

A clinician talks about reducing antibiotic treatment duration for urinary tract infections (UTI).


Laila Woc-Colburn, MD, associate professor, Emory University School of Medicine, points out 2 existing issues around treating UTIs: overtreatment which has led to resistance and duration of treatment.

Her latter point is one of the emerging treatment patterns in looking at opportunities to decrease antibiotic duration for infections. “The treatment that used to be 10-14 days has come down to 3-5 days,” Woc-Colburn said for UTIs. “And antibiotics like fosfomycin, given once, stays in the system for 72 hours. You are looking at short, not complicated regimens that are going to help you decrease the pressure for gram-negative bacteria resistance.”

Woc-Colburn presented a scientific session, Urine Trouble: What's New in Treating Urinary Tract Infections? at this year’s ACP conference.

She also mentions the challenging pipeline for UTI therapies in development. “We will have a narrow pipeline that more geared towards gram-negative, multidrug-resistant bacteria,” Woc-Colburn explained.

As such, she believes clinicians and patients would be best served using antibiotics judiciously and determining when to treat and for how long.

Contagion spoke to Woc-Colburn who offered insights on decreasing antibiotic duration, investigational therapies for UTIs, considerations for clinical guidance, and treatment strategies to change the vaginal microbiome.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.